you are here:

Ipca Laboratories Ltd.

BSE: 524494 | NSE: IPCALAB |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE571A01020 | SECTOR: Pharmaceuticals

BSE Live

Apr 09, 16:00
2070.90 7.20 (0.35%)
  • Prev. Close


  • Open Price


  • Bid Price (Qty.)

    2070.20 (10)

  • Offer Price (Qty.)

    2085.10 (106)

NSE Live

Apr 09, 15:58
2086.00 25.80 (1.25%)
  • Prev. Close


  • Open Price


  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    2086.00 (388)

Company History - Ipca Laboratories
One of the first modern pharma factory of yesteryears was commissioned
 by Ipca at Mumbai in 1969.  The company was originally promoted by a
 group of medical professionals and businessmen and was incorporated
 as 'The Indian Pharmaceutical Combine Association Limited.' in
 October 1949. The present management took over in November 1975 when
 the total turnover of the company was just Rs. 0.54 crores.
 Currently, this premise where Ipca started its operations, houses the
 Registered Office of the company. Key departments like International
 Marketing, R&D (Formulations) and Analytical Development Lab are
 located here. 
 YEAR                       EVENTS
 1949 - Ipca Laboratories Ltd. was incorporated on 19th October, in
 Mumbai, under the name `The Indian Pharmaceutical Combine Association
 Limited'.  The Company manufacture pharmaceutical products such as
 tablets, capsules, vials and ampoules.  The Company was promoted by a
 group of medical professionals viz., Dr. N.K. Chaina, Dr. A.M. Desai,
 Dr. N.S. Tibrawala, K.M. Shroff, S.F. Kirawal, U.H. Dalal and K.B.
 1964 - The name was subsequently changed to `Ipca Laboratories Ltd.'
 on 6th August 1964.  The name was further changed to `Ipca
 Laboratories Private Limited' on 13th January 1966.  The name of the
 company was again changed to `Ipca Laboratories Ltd.' on 9th August
 1988.  The company became a Public Limited Company on 24th March,
 1975 - The management of the company was taken over by Amitabh
 Bachchan, Ajitabh Bachchan, Jaya Bachchan, M.R. Chandurkar, P.C.
 1994 - The Company undertook to set up a modern plant at Athal,
 Silvassa, for manufacture of pharmaceutical formulations.  Plant and
 machinery comprising blenders, auto tablet coaters, fluid bed dryers,
 etc., procured indigenously.  The Tatlam bulk drug unit capacity was
 increased to 500 TPA.
 1995 - 9,225,000 No. of equity shares allotted to promoters, friends,
 relatives and associates (of these, 225,000 were Rights shares at a
 premium of Rs 120 per share).  During February, the Company issued
 3,275,000 No. of equity shares of Rs 10 each at a premium of Rs 120
 per share of which 150,000 shares reserved for allotment on a
 preferential basis to employees of the Company (all were taken up). 
 Balance 3,125,000 shares issued to the public (all were taken up).
 2002-R S Hugar, former managing director of Global Trust Bank, has
 joined the board of directors of Ipca as non-executive chairman with
 effect from June 11, 2002. 
 -Launched new domestic marketing division, ACTIVA , dedicated to
 Rheumatology Care. First Company in India to have such division for
 marketing superspeciality molecules.  
 - Launched new domestic marketing division,Hy Care  dedicated to
 Cardio-Diabetology segments. 
 - Wholly owned subsidiary Ipca Pharmaceuticals Inc. incorporated in
 United States of America. 
  -Wholly owned subsidiary Ipca Laboratories (UK) Ltd. incorporated
 in United Kingdom. 
 - Forbes, a leading US business magazine, selected among its top 200
 successful, rising companies outside USA, with sales under USD 1
 -Members of the Company have approved the amalgamation in the nature
 of merger of Innotech Pharma Ltd., a 100% subsidiary of the Company,
 with Company
 -Ipca Laboratories Ltd. unveils novel injectable antibiotic
 combination of cefotaxime sodium with sulbactam sodium for the first
 time in the country under the brand name 'Sultax'
 -Received 'Lifetime Achievement Award' for the year2002-03 from from
 CHEMEXIL (Basic Chemicals,Pharmaceuticals & Cosmetics Export
 Promotion Council)for export promotion over the years.
 -Commissioned new formulation plant at Silvassa
 -Forbes Asia, a leading US business magazine selected Ipca, for the
 second consecutive year as one among the first 200 'Best under a
 Billion Company' in Asia
 -Ipca Laboratories Ltd has informed that the Company has entered into
 a Joint Venture (JV) agreement with Chongqing Holley Holding Company
 Ltd of China. 
 -Merger of Innotech Pharma Limited with Ipca Laboratories Limited in
 August, 2005.
 -Acquires Cardiac brand ISORDIL from Wyeth Limited.
 -Forbes Asia, a leading US business magazine selected Ipca, for the
 third consecutive year as one among the first 200 'Best under a
 Billion Company' in Asia.
 - Ipca Laboratories has given the Bonus in the Ratio of 1:1
 -Ipca Laboratories Enters into Strategic Alliance with Ranbaxy
 Pharmaceuticals Inc., for the US Market
 -Ipca Laboratories launches fixed dose ACT combination and stops
 manufacturing of single ingredient Oral Artemisinin derivatives.
 -Ipca's new plant at Dehradun commenced operation on 5th May, 2006
 -Ipca - Ranbaxy Alliance received U.S. FDA marketing approval for
 Atenolol Tablets
 -Ipca Laboratories granted US FDA approval for Hydroxychloroquine
 sulfate tablet
 -Ipca Laboratories - Acquisition of 100% shareholding of formulation
 dossier registration holding companies in Australia and N
 -Ipca launched eighth domestic marketing division, 'Altus' which
 caters to intensivists and surgeons.
 -Ipca has been awarded by Forbes Inc., as one of the 'Best under a
 Billion' Forbes Global's 200 Best Small Companies, 2007. In the past,
 company has received same award for three consecutive years' 2003,
 2004 and 2005.
 -Ipca Laboratories receives US FDA approval for Propranolol
 Hydrochloride Tablets
 -Tonira Pharma's Nandesari unit (API plant at Baroda) receives US-FDA
 -Ipca Laboratories Ltd has re-appointed Mr. Premchand Godha as the
 Managing Director of the Company for a further period of 5 years
 w.e.f. April 01, 2008.
 -Ipca-Piparia, formulation manufacturing unit receives MHRA-UK
 approval. This is the 3rd plant after Athal and Kandla receiving this
 -WHO prequalify Ipca's dossier of ARTESUNATE + AMODIAQUINE Co Blister
 making Ipca the 2nd company in the world and the first Indian company
 to receive this prequalification. 
 -Ipca received Best Patent Award during the year 2007 - 08
 - Ipca Laboratories Ltd has informed that the Board of Directors of
 the Company at its meeting held on January 21, 2010, inter alia,
 appointed Mr. Anand T Kusre as a Director of the Company.
 -Company has splits its Face value of Shares from Rs 10 to Rs 2
 -Ipca Laboratories has received approval from UK Medicines and
 Healthcare Products Regulatory Agency for its fourth manufacturing
 unit at a Special Economic Zone in Indore for good manufacturing
 practices under the regulator.
 -Ipca labs bags nod to amalgamate Tonira Pharma
 -Mr. Dev Parkash Yadava has been appointed as an Additional Director
 of the Company
 -IPCA Laboratories bags USFDA nod Indore formulations manufacturing
 -IPCA received Corporate Citizen Award' for best corporate governance
 -IPCA  Dehradun won the Energy Conservation Award for the 3rd year in
 a row.
 -IPCA  featured on the 8th position in the list of 'India's Most
 Admired Companies, in a survey carried out by Fortune India, in
 collaboration with The Hay Group, for the second time.
 -IPCA Laboratories said that SEZ Indore formulations manufacturing
 unit has been found acceptable after the inspection of US-FDA.
 -IPCA Laboratories  Acquisition of High Potency Oral Solid Dosage
 formulations manufacturing unit situated at Pithampur near Indore.
 -IPCA has entered into an alliance with Oncobiologics, Inc. USA for
 the development, manufacture and commercialization of biosimilar
 monoclonal antibody products. 
 -IPCA Sports Club wins the E-Merck Inter-Pharma Cricket Tournament.
 -IPCA  acquires formulations manufacturing unit located at Tarapur,
 Dist. Palghar, Maharashtra.
 -IPCA Sports Club wins Dreamz Trophy (T-20 & 40-overs format).
 -New product Launch - Pacimol Active
 -Whistle Blower Policy implemented.
 -Ipca Lab wins Clinical and Research Excellence (CARE) awards.
 -Ipca was awarded by 'Indian Drug Manufacturers Association (IDMA)
 Best Formulation Patent (2014-15)' for its formulation patent of
 Hydroxychloroquine and its combinations in treatment of Diabetes
 Mellitus at 54th IDMA annual day celebration held on 23rd January
 -Ipca Laboratories wins the 'Clinical Trial result of the year' at
 the first annual CARE Award held at Boston, USA on 27th April 2016.
 -Ipca's Ratlam manufacturing Unit won 1st prize in National Energy
 Conservation Award 2016. This ceremony was hosted in Delhi on 14th
 December 2016.
 -Ipca Laboratories has been conferred with Intellectual Property (IP)
 Excellence Award 2016 for adopting The Best Practices in IP
 Intelligence in a function organized in Mumbai on November 28th,
 - Ipca's Revelol Am NH2 Programme (National Healthy Heart Programme)
 has entered Limca Book of Records-December 2017.
 -Ipcas domestic marketing division, Intima launched brand Platigain.
 It is one more gem in the crown of Intima division.
 -Ipca  Launched launch  two new offsprings Pacimol MF tablets and
 Pacimol IV.
 - Ipca received Fastest Growing Business Award 2017  during a Trade
 Meet of Renowned Liners with Exporters.